What Is FDA's 503A Bulks List?
The list that decides which ingredients compounding pharmacies can legally use. How it works, which peptides are on it (none yet), and what the July 2026 vote and the October 2026 HHS draft policy actually change.
- No peptides on the list yet
- 6 allowed by Rx under a draft HHS policy
- Next PCAC review by Feb 2027

Educational content only, not legal or medical advice. Regulatory status can change; verify current status with FDA or a qualified pharmacist.
The quick answer
| What the 503A Bulks List is | What it is not |
|---|---|
| An FDA list of bulk drug substances pharmacies can legally use for traditional compounding | A list of FDA-approved drugs |
| One of three legal pathways for compounding a substance under Section 503A | The only pathway; a USP-NF monograph or use in an approved drug also qualify |
| Changed only through nomination, expert review and formal rulemaking | Something one advisory committee vote can change on its own |
Section 503A, explained
Traditional compounding: a pharmacist preparing a specific medication for one patient's prescription, not manufacturing a drug for general sale.
A bulk ingredient generally has to meet one of three conditions:
On the 503A Bulks List
FDA's Section 503A Bulk Drug Substances List, set out in 21 CFR 216.23.
Has a USP-NF monograph
An official standard in the United States Pharmacopeia-National Formulary.
Part of an approved drug
A component of a drug FDA has already approved.
If a substance meets none of the three, a 503A pharmacy generally cannot use it, whatever the demand or perceived safety.
How a substance gets added
A multi-step process, not a decision FDA makes overnight.
Nomination
Any interested party, such as a pharmacy, trade group or manufacturer, formally nominates a substance.
FDA evaluation
FDA reviews the nomination and the evidence submitted with it.
PCAC referral
FDA often refers it to its Pharmacy Compounding Advisory Committee, a panel of outside experts.
Committee vote
PCAC votes on a recommendation. The vote is nonbinding; FDA does not have to follow it.
Proposed rule
If FDA moves forward, it publishes a proposed rule and opens public comment.
Final rule
Only a final rule actually adds the substance to the list.
The July 2026 vote on seven peptides
PCAC met July 23 and 24, 2026, and recommended six of seven, mostly by narrow margins.
| Peptide | Day reviewed | Reported vote | Recommendation |
|---|---|---|---|
| BPC-157 | Jul 23 | 8 yes, 6 no, 1 abstain | Recommended |
| KPV | Jul 23 | 8 yes, 6 no, 1 abstain | Recommended |
| TB-500 | Jul 23 | 8 yes, 6 no, 1 abstain | Recommended |
| MOTS-c | Jul 23 | 7 yes, 5 no, 2 abstain | Recommended |
| Semax | Jul 24 | 8 yes, 5 no, 1 abstain | Recommended |
| Epitalon | Jul 24 | 7 yes, 4 no, 1 abstain | Recommended |
| Emideltide (DSIP) | Jul 24 | 6 yes, 7 no, 1 abstain | Not recommended |
Tallies as reported by Reuters and McDermott Will & Schulte. The vote itself did not make compounding legal. Full story: what changed with BPC-157, TB-500 and MOTS-c in 2026.
Which peptides are on the list?
None of the 2026 peptides. 21 CFR 216.23 still holds only the six substances added in 2019.
| Peptide | Where it stands | On the list? |
|---|---|---|
| BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon | Recommended by PCAC; awaiting FDA rulemaking. Rx compounding allowed meanwhile under the draft HHS policy | Not yet (draft policy) |
| Emideltide (DSIP) | PCAC voted against it in July 2026 | No |
| LL-37, GHK-Cu, Dihexa, Melanotan II, PEG-MGF | Set for PCAC review before the end of February 2027 | Not yet |
No date or Federal Register notice had been published for the next meeting as of late October 2026. Check FDA's PCAC page or our FDA peptide status tracker.
The October 2026 HHS draft policy
Announced October 28 and published in the Federal Register October 30, 2026 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496).
HHS says it does not intend to take action against licensed 503A pharmacies that compound these six peptides for individual patients with a valid prescription, if they meet the policy's conditions, while FDA completes rulemaking.
| Peptide | Allowed routes |
|---|---|
| BPC-157 | Injection, oral, topical |
| TB-500 | Injection |
| MOTS-c | Injection |
| KPV | Topical, oral |
| Semax | Nasal spray |
| Epitalon | Injection, intermittent courses |
- One peptide per product. No blends.
- Sourcing: from an FDA-registered manufacturer following current good manufacturing practice.
- Full testing: identity, purity, potency, impurities, microbes and endotoxin.
- Label: "This is a compounded drug product. Not for resale."
- Reporting: serious adverse events go to FDA's MedWatch program.
It is a draft: nonbinding, and HHS can revise or withdraw it. Comments were open for two weeks after publication, until about November 13, 2026. Summary: Frier Levitt.
What it really means
- Does mean: a licensed pharmacy can prepare the substance for a patient with a valid prescription, under its own quality and licensing rules.
- Not FDA approval: no clinical trial review of safety or effectiveness.
- Not over the counter: 503A is built entirely around individual prescriptions.
- Not 503B or research chemicals: the draft policy covers neither outsourcing facilities nor "research use only" sellers.
- Not the list: formal addition still needs a proposed and final rule, expected to take roughly 12 to 24 months.

How patients get them
Under the draft policy, the legal route for these six peptides runs through a licensed prescriber and a licensed 503A compounding pharmacy, not a research chemical website.
- How to get peptides legally: the practical steps
- What is a compounded peptide? vs a research chemical
- Are peptides legal in 2026? the full legal picture

Frequently asked questions
What is the 503A Bulks List?
The Section 503A Bulk Drug Substances List, often called the 503A Bulks List, is an FDA list of bulk drug substances that licensed pharmacies can use in traditional compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. A substance generally has to appear on this list, have an official USP-NF monograph, or be a component of an FDA-approved drug before a compounding pharmacy can legally use it to fill an individual patient's prescription.
Which peptides are on the 503A Bulks List?
None of the peptides reviewed in 2026 are on it yet. As of October 31, 2026, the list in 21 CFR 216.23 still holds only the six substances added in 2019. PCAC recommended BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon in July 2026 and voted against Emideltide (DSIP), but FDA has not published a proposed or final rule adding any of them. Those six can be compounded by prescription in the meantime under a draft HHS policy.
Is BPC-157 on the 503A Bulks List?
No. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 for the list, but that recommendation is nonbinding and FDA has not completed rulemaking. Separately, a draft HHS policy announced October 28, 2026 lets licensed 503A pharmacies compound BPC-157 by prescription under strict conditions while that rulemaking is pending.
Who decides what gets added to the list?
FDA makes the final decision, but the process starts when an interested party formally nominates a substance. FDA often refers the nomination to its Pharmacy Compounding Advisory Committee (PCAC) for a recommendation vote, which is advisory only. If FDA moves forward, it must complete notice-and-comment rulemaking, including a proposed rule and public comment, before a final rule adds the substance to the list.
What happened at the July 2026 FDA meeting?
The Pharmacy Compounding Advisory Committee met July 23 to 24, 2026, to review seven peptides nominated for the 503A Bulks List: BPC-157, KPV, TB-500 and MOTS-c on the first day, and Emideltide (the nomination name used for DSIP), Semax and Epitalon on the second. The committee recommended six of the seven, all except Emideltide, mostly by narrow margins.
Does being recommended for the list mean a peptide is legal to compound now?
Not by itself. A PCAC recommendation is a nonbinding suggestion to FDA, not a legal change. What allows compounding now is a separate draft HHS policy announced October 28, 2026, which covers the six recommended peptides by prescription under strict conditions. Being added to the list in the future would not make a substance FDA-approved or available over the counter either.
What is the October 2026 HHS draft policy for peptides?
On October 28, 2026, HHS announced a draft enforcement discretion policy, published in the Federal Register on October 30, that lets licensed 503A pharmacies compound BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon for individual patients with a prescription, under strict conditions on sourcing, testing, routes, labeling and adverse event reporting. It does not add them to the 503A Bulks List and does not cover 503B facilities or research chemical sellers.
Which peptides will FDA review next for the 503A Bulks List?
FDA says its Pharmacy Compounding Advisory Committee will meet before the end of February 2027 to discuss LL-37 (cathelicidin), GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF. As of late October 2026, no exact date or Federal Register notice had been published.
Plan it, then track it
Build a protocol to bring to your prescriber, then log doses and check-ins in one place. Free.
Sources
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, October 30, 2026 (FR Doc. 2026-22192). federalregister.gov
- 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meetings. fda.gov
- Frier Levitt. HHS Peptide Compounding Enforcement Discretion Policy, October 2026. frierlevitt.com
This content is for informational purposes only and is not legal or medical advice. Consult a qualified attorney, pharmacist or healthcare provider. FDA regulatory status can change after this was written; verify current status directly with FDA.